Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.

• Installations at National Taiwan University and National Cheng Kung University expand Nuclera’s global footprint with first commercial sales in Asia
• System strengthens Taiwan’s capabilities in protein drug discovery research

Change in role from Chief Data Officer reflects Qureight’s continued growth and commercial success in delivering customers’ clinical studies

LONDON, UK  – January 7, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.

Ikarovec to advance pipeline with exclusive worldwide option to VectorBuilder’s Intravitreal Capsid Technology

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease

We’re kicking off the new year with a full calendar of courses covering a broad mix of skills. Whether you’re looking to sharpen existing expertise or explore something new, there’s something for everyone to discover and learn throughout the year.

27 January 2026 | The Safe Use and Management of Laboratory Gases Register Here...

Calling all academics, clinicians, entrepreneurs, start-ups, and industry partners who want to turn early-stage medical technologies into safe, sustainable, clinically ready devices.